How Adapthealth Corp. (AHCO) Affects Rotational Strategy Timing
This article analyzes Adapthealth Corp. (AHCO) and its impact on rotational strategy timing, identifying weak near- and mid-term sentiment but a strong long-term outlook. It presents specific AI-generated trading strategies including long, breakout, and short positions, complete with entry zones, target prices, and stop losses. The analysis also provides multi-timeframe signal strengths and support/resistance levels.
What's Driving the Recent Buzz Around AdaptHealth (AHCO)
One Equity Partners (OEP VII GP), a significant 10% owner of AdaptHealth (AHCO), has shown strong confidence in the company by purchasing over $24 million worth of shares in March 2026, despite recent mixed financial results and a Q4 2025 GAAP loss. This insider buying signals a belief in AHCO's long-term value, driven by a strategic large-scale capitated contract and record patient census in key health segments, which are expected to fuel future growth. The article highlights the conflicting valuation models and analyst sentiments, suggesting that OEP's aggressive investment may indicate an unappreciated upside for AdaptHealth as it navigates operational changes and invests for future expansion.
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know
Repligen, AdaptHealth, and IQVIA stocks experienced declines after a report indicated accelerating wholesale inflation, specifically a 6% annual rise and a 1.2% monthly increase in service-sector prices. This inflation impacts healthcare companies by increasing operating costs and raising concerns about potential regulatory intervention on drug pricing. Despite the market overreaction, such price drops can present buying opportunities for high-quality stocks.
Canaccord Lifts PT on AdaptHealth Corp. (AHCO) Following Q1 Results
Canaccord has increased its price target for AdaptHealth Corp. (AHCO) to $16 from $14, reiterating a Buy rating after the company released its fiscal Q1 2026 results. Despite an EBITDA miss that caused a stock pullback, the firm believes AdaptHealth is well-positioned in the DME market, especially with growing demand for capitated agreements. AdaptHealth reported net revenue of $819.8 million for Q1 2026, an increase of 5.4%, and 9.1% organic revenue growth.
Transcript : AdaptHealth Corp. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09
AdaptHealth Corp. presented at the Bank of America Global Healthcare Conference 2026. The company is identified as one of the largest medical equipment providers in the U.S. The full transcript of this presentation is available only to subscribers.
AHCO Maintained by RBC Capital -- Price Target Raised to $15.00
RBC Capital has maintained an "Outperform" rating on AdaptHealth (AHCO) and raised its price target from $13.00 to $15.00, reflecting continued confidence in the company. Although AHCO is considered modestly overvalued by its GF Value, its GF Score of 75/100 indicates solid performance, particularly in momentum, and significant insider buying activity suggests positive expectations for future performance. Investors should weigh the positive analyst outlook against the current valuation metrics.
AdaptHealth Corp. (NASDAQ:AHCO) Receives Average Rating of "Moderate Buy" from Analysts
AdaptHealth Corp. (NASDAQ:AHCO) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $14.00. The company's recent quarterly results showed revenue of $819.8 million, exceeding expectations, though EPS of -$0.12 missed estimates. Insider buying, including a significant purchase by major shareholder Richard M. Cashin, Jr., and substantial institutional ownership, indicate strong internal and external confidence in the stock.
(AHCO) and the Role of Price-Sensitive Allocations
This article analyzes Adapthealth Corp. (NASDAQ: AHCO), highlighting a weak near- and mid-term sentiment but a strong long-term positive outlook. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with defined entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal analysis indicating support and resistance levels for the stock.
AdaptHealth (AHCO) Boosts 2026 Outlook and Refinances Debt Is Its Growth Strategy Evolving?
AdaptHealth Corp. (AHCO) reported Q1 net revenue of US$819.8 million and a wider net loss, while also completing a US$1.10 billion refinancing of its credit facility and raising its 2026 net revenue guidance to US$3.45 billion–US$3.52 billion. The refinancing aims to support disciplined acquisitions in Sleep and Respiratory Health and de novo expansion, with management suggesting this strengthens their growth strategy despite ongoing margin pressure and capital intensity risks. Investors are encouraged to consider diverse perspectives on the stock's future, as analysts project varying revenue and earnings figures for 2028-2029.
AdaptHealth (NASDAQ:AHCO) Beats Q1 CY2026 Sales Expectations
AdaptHealth (NASDAQ:AHCO) reported Q1 CY2026 revenue of $819.8 million, exceeding analyst expectations by 2.9%, although it posted a GAAP loss of $0.12 per share, significantly missing estimates. The company slightly increased its full-year revenue guidance to $3.49 billion and maintained its EBITDA guidance. Despite mixed results and a 2.8% immediate stock drop, analysts anticipate improved revenue growth for AdaptHealth in the next year.
AdaptHealth (AHCO) Boosts 2026 Outlook and Refinances Debt Is Its Growth Strategy Evolving?
AdaptHealth Corp. recently reported its first-quarter 2026 results, showing increased net revenue but a wider net loss. The company refinanced its senior secured credit facility for $1.10 billion, lowering interest costs and extending maturities, and raised its 2026 net revenue guidance to between $3.45 billion and $3.52 billion. This move aims to support disciplined acquisitions in core Sleep and Respiratory Health, de novo expansion, and a digital patient engagement platform, suggesting an evolving growth strategy focused on strengthening its balance sheet and targeted acquisitions.
AdaptHealth (AHCO) Boosts 2026 Outlook and Refinances Debt Is Its Growth Strategy Evolving?
AdaptHealth (AHCO) recently reported its first-quarter 2026 results, including a wider net loss despite increased revenue, and refinanced its senior secured credit facility for $1.10 billion. The company also raised its 2026 net revenue guidance, emphasizing disciplined tuck-in acquisitions and de novo expansion to support its growth strategy. Investors are encouraged to consider how these financial moves and updated guidance impact the company's valuation and risk profile.
AdaptHealth's 10 million-member rollout came with $12M in labor costs
AdaptHealth Corp. announced first-quarter 2026 financial results, reporting a 5.4% increase in net revenue to $819.8 million. The company completed a significant de novo expansion, serving over 10 million members for a new strategic partner, which incurred $12 million in elevated labor expenses expected to normalize by Q2. AdaptHealth also raised its full-year 2026 net revenue guidance and completed a $1.1 billion refinancing of its senior secured credit facility.
Stocks making big moves yesterday: Cogent, AdaptHealth, BWX, IQVIA, and Palantir Technologies
This article highlights several stocks that experienced significant price movements yesterday based on their recent financial reports and analyst upgrades. Cogent and IQVIA saw increases due to strong results and an upgrade, while AdaptHealth, BWX, and Palantir Technologies experienced declines despite some beating expectations, illustrating varied market reactions to quarterly earnings.
AHCO | AdaptHealth Corp. Common Stock Financials - Income Statement
The article provides financial information for AdaptHealth Corp. (AHCO), including an income statement, and details of congressional insider trading activities related to the stock. It lists several transactions by politicians Kevin Hern and Susie Lee. The company provides patient-centered, healthcare-at-home solutions across four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home.
AHCO Investor News: Rosen, Trusted National Trial Counsel, Encourages AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AHCO, A
The Rosen Law Firm is reminding investors of AdaptHealth Corp. (AHCO, AHCOW) who suffered losses exceeding $100K to secure counsel before the September 27, 2021 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that AdaptHealth misrepresented its organic growth and overstated its financial prospects during the Class Period from November 11, 2019, to July 16, 2021. Investors who purchased securities during this period may be entitled to compensation.
Stocks making big moves yesterday: Cogent, AdaptHealth, BWX, IQVIA, and Palantir Technologies
This article highlights several companies that experienced significant stock movements yesterday. Cogent and IQVIA saw rises due to upgrades and strong financial results, respectively. In contrast, AdaptHealth, BWX, and Palantir Technologies experienced drops despite some beating expectations, citing factors like disappointing earnings and "buy the rumor, sell the news" scenarios.
Stocks making big moves yesterday: Cogent, AdaptHealth, BWX, IQVIA, and Palantir Technologies
This article highlights several companies that experienced significant stock movements yesterday following their respective financial news. Cogent and IQVIA saw increases due to analyst upgrades and strong earnings, while AdaptHealth, BWX, and Palantir Technologies experienced drops despite some beating expectations, pointing to market reactions to nuanced financial results.
AdaptHealth Corp. (NASDAQ:AHCO) Q1 2026 Earnings Call Transcript
AdaptHealth Corp. (NASDAQ:AHCO) reported its Q1 2026 earnings, missing EPS expectations with $-0.06 but exceeding revenue guidance, reaching $819.8 million, a 5.4% increase year-over-year. The company successfully executed a large patient transition under a new capitated agreement, leading to significant organic growth, particularly in Sleep Health, and emphasized strategic investments in infrastructure and technology. Despite elevated labor costs impacting adjusted EBITDA in Q1, AdaptHealth maintained its full-year adjusted EBITDA and free cash flow guidance due to expected cost normalization and increased revenue projections.
Deutsche Bank Adjusts AdaptHealth Price Target to $12 From $9.50, Maintains Hold Rating
Deutsche Bank has increased its price target for AdaptHealth (AHCO) to $12, up from the previous $9.50, while reiterating its "Hold" rating on the stock. This adjustment reflects a revised outlook from the bank regarding the healthcare company's valuation. The news follows AdaptHealth's recent financial results, including widened Q1 losses but increased net revenue and lifted 2026 net revenue guidance.
Press Release: AdaptHealth Corp. Announces First Quarter 2026 Results
AdaptHealth Corp. has announced its financial results for the first quarter of 2026. The company will likely detail key financial metrics, operational highlights, and potentially provide guidance for the upcoming periods. This press release will be of interest to investors and market analysts following AdaptHealth's performance.
Why AdaptHealth (AHCO) Shares Are Sliding Today
AdaptHealth (AHCO) shares fell 8.5% after the company reported disappointing Q1 2026 results, including a significant earnings miss and worsening profitability despite a revenue beat. The GAAP loss per share was $0.12, far worse than analyst estimates. Although revenue increased by 5.4% to $819.8 million, the operating margin contracted sharply, and the company experienced increased cash burn, leading to investor concerns about rising costs and operational efficiency.
Stocks making big moves yesterday: Cogent, AdaptHealth, BWX, IQVIA, and Palantir Technologies
This article highlights several stocks that experienced significant movement yesterday, including Cogent, AdaptHealth, BWX, IQVIA, and Palantir Technologies. Each company's stock performance is briefly explained, often linked to quarterly earnings reports or analyst upgrades. The article provides a quick overview of why these companies were in the news.
AHCO Q1 Deep Dive: Capitated Growth Boosts Revenue, Margin Pressust Persist
AdaptHealth Corp. delivered strong Q1 CY2026 revenue driven by a large capitated contract, exceeding Wall Street expectations. However, the rapid onboarding of this contract led to elevated labor costs and a significant miss on adjusted EPS and EBITDA. Management anticipates margin improvements in the latter half of the year and into 2027 as operational efficiencies from technology investments take effect and labor costs normalize.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 27, 2021 - AHCO
Levi & Korsinsky, LLP has announced a class action lawsuit against AdaptHealth Corp. (AHCO) for shareholders who acquired securities between November 11, 2019, and July 16, 2021. The lawsuit alleges that AdaptHealth misrepresented its financial prospects by inflating organic growth numbers and violating SEC regulations. Shareholders who suffered losses have until September 27, 2021, to request to be appointed as lead plaintiff.
[10-Q] AdaptHealth Corp. Quarterly Earnings Report
AdaptHealth Corp. (AHCO) filed its quarterly earnings report (10-Q) for the period ended March 31, 2026. The report details the company's financial performance, including a net loss of $16.04 million for Q1 2026, compared to a net loss of $7.21 million in Q1 2025. Total net revenue increased by 5.4% to $819.8 million, driven by organic growth and acquisitions, but partially offset by dispositions.
AdaptHealth schedules two investor fireside chats in May, with webcasts
AdaptHealth Corp. announced its participation in two investor conferences in May 2026. The company will present at the Bank of America Global Healthcare Conference on May 12th and the RBC Global Healthcare Conference on May 19th, both featuring fireside chats. Webcasts for these events will be available on AdaptHealth's investor relations website.
Why AdaptHealth (AHCO) Shares Are Sliding Today
AdaptHealth Corp. (NASDAQ:AHCO) shares fell 8.5% after reporting disappointing first-quarter 2026 results. The company missed analyst consensus estimates for GAAP loss per share and experienced a significant contraction in operating margin, despite a revenue beat. These results, coupled with increased cash burn, raised investor concerns about profitability and operational efficiency.
AdaptHealth sets stage for ‘defining year’
AdaptHealth reported Q1 2026 revenue of $819.8 million, a 5.4% increase year-over-year, despite a net loss of $16.0 million and a 5.3% decrease in Adjusted EBITDA. The company completed its largest de novo expansion and refined its portfolio, leading CEO Suzanne Foster to declare 2026 a "defining year." AdaptHealth raised net revenue guidance for fiscal year 2026 to $3.45 billion to $3.52 billion.
Earnings call transcript: AdaptHealth Q1 2026 results miss EPS, stock drops
AdaptHealth Corp (AHCO) reported Q1 2026 earnings with an EPS of -$0.12, significantly missing the forecast of $0.01, despite exceeding revenue expectations with $819.8 million. The stock dropped 13.57% in premarket trading due to investor concerns over profitability, influenced by elevated labor costs from a new capitated contract transition. Despite these challenges, the company raised its full-year revenue guidance and anticipates margin expansion in Q2 as transition costs normalize.
AdaptHealth Releases Q1 2026 Financial Results
AdaptHealth Corp. (AHCO) reported Q1 2026 diluted earnings of -$0.12 per share, significantly missing the consensus estimate of $0.02, representing a 1300.0% miss. The company's revenue for the quarter was $819.8 million, showing a 5.4% year-over-year increase, with organic revenue growth of 9.1%. AdaptHealth expects full-year revenue to be between $3.45 billion and $3.52 billion.
AdaptHealth (NASDAQ: AHCO) Q1 2026 results, raises revenue outlook and names new COO
AdaptHealth Corp. announced its Q1 2026 financial results, reporting a 5.4% increase in net revenue to $819.8 million and 9.1% organic revenue growth. Despite the revenue growth, the company's net loss widened, and Adjusted EBITDA and free cash flow declined due to increased investments. AdaptHealth also raised its full-year 2026 net revenue outlook and appointed Daniel McFadden as the new Chief Operating Officer following the termination of Toby Scott Barnhart.
Adapthealth Corp stock hits 52-week high at $13.40 By Investing.com
AdaptHealth Corp. stock has reached a 52-week high of $13.40, reflecting a 50% total return over the last 12 months and a 32% gain year-to-date. Despite this surge, InvestingPro analysis suggests the stock remains undervalued with further upside potential. This comes after AdaptHealth reported a significant EPS miss in Q4 2025 but exceeded revenue expectations and closed a new $1.1 billion credit facility.
AdaptHealth earnings up next: Can home health provider return to profit?
AdaptHealth Corp. is set to report its first-quarter earnings, with analysts expecting a return to profit at $0.01 per share on revenue of $796.29 million, following a significant loss in the fourth quarter. Investors will be focused on improved profitability, revenue trends, and updates on the newly acquired Hawaiian capitated contract, alongside the company's strengthened balance sheet. The home durable medical equipment market is projected for continued growth, providing a favorable industry environment for AdaptHealth.
AdaptHealth (AHCO) Reports Earnings Tomorrow: What To Expect
AdaptHealth Corp. (AHCO) is scheduled to release its Q1 earnings tomorrow morning. Analysts expect the company's revenue to grow 2.5% year-on-year, a turnaround from last year's decrease, despite missing Wall Street's revenue estimates multiple times in the past two years. The senior health, home health & hospice segment has shown positive investor sentiment recently, with AdaptHealth's stock up 9.1% over the last month.
Responsive Playbooks and the AHCO Inflection
This article from Stock Traders Daily provides an AI-driven analysis of Adapthealth Corp. (NASDAQ: AHCO), indicating strong sentiment across all horizons despite elevated downside risk due to a lack of long-term support signals. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
AdaptHealth (NASDAQ: AHCO) CTO corrects share count in Form 4/A filing
AdaptHealth Corp.'s Chief Technology Officer, Albert A. Prast, filed an amended Form 4 to correct his reported share ownership. The amendment clarifies that a prior disposition of 58,203 shares at $10.33 per share was for tax withholding, not an open-market sale. After correcting this and a previous overstatement of 135,443 shares, Prast's direct beneficial ownership now stands at 338,712 shares of common stock.
Is It Time To Reassess AdaptHealth (AHCO) After A 60% One Year Rally?
AdaptHealth (AHCO) has seen a significant 60% rally over the past year, prompting a reassessment of its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 64.0%, while its P/S ratio indicates a modest discount compared to a proprietary fair ratio. The article also presents bullish and bearish narratives, with fair values ranging from US$9.50 to US$17.00 per share, offering investors different perspectives on the company's future.
AdaptHealth (AHCO) Expected to Announce Earnings on Tuesday
AdaptHealth (AHCO) is slated to release its Q1 2026 earnings before market open on Tuesday, May 5th, with analysts projecting $0.0113 EPS and $796.63 million in revenue. The company had a significant EPS miss in the prior quarter despite exceeding revenue estimates, leading to an average "Hold" rating from analysts with a target price of $13.00. Notable insider activity includes a major shareholder increasing their position in March, and institutional investors currently holding approximately 82.67% of the company's stock.
AdaptHealth to Report First-Quarter 2026 Results on May 5
AdaptHealth Corp. (NASDAQ: AHCO) is scheduled to release its first-quarter 2026 financial results before the market opens on Tuesday, May 5, and will host a conference call at 8:30 a.m. ET to discuss these results. The company provides home-based healthcare services to approximately 4.3 million patients annually across all 50 states, specializing in sleep health, respiratory health, diabetes health, and wellness at home.
AdaptHealth refinances $1.1B senior secured credit facility
AdaptHealth has successfully refinanced its $1.1 billion senior secured credit facility. This strategic move aims to extend the maturity of its debt and enhance financial flexibility, supporting the company's long-term growth and operational stability.
Adapthealth Corp stock hits 52-week high at 12.87 USD By Investing.com
AdaptHealth Corp's stock has reached a new 52-week high of $12.87, representing a 58.5% total return over the past year. Despite a recent miss in Q4 2025 EPS, the company reported a slight revenue beat and secured a new $1.1 billion senior secured credit facility. Analysts have mixed views, with Leerink Partners lowering their price target while RBC Capital maintained an Outperform rating.
New Credit Facility and Rating Upgrades Might Change The Case For Investing In AdaptHealth (AHCO)
AdaptHealth (AHCO) recently secured a new US$1.10 billion senior secured credit facility, extending debt maturities and potentially reducing borrowing costs, following rating upgrades. This new facility aims to enhance the company's financial flexibility and support its shift towards home-based care, despite past losses and regulatory exposure. While it could aid in funding infrastructure for a large national health system contract, investors are advised to consider ongoing reimbursement pressures from CMS decisions.
Adapthealth Corp stock hits 52-week high at 12.87 USD
AdaptHealth Corp (AHCO) stock reached a new 52-week high of $12.87, reflecting a strong performance with a 58.5% total return over the past year. Despite previous misses in EPS expectations and revised price targets from analysts like Leerink Partners, the company's strategic developments, current undervaluation based on InvestingPro metrics, and a new $1.1 billion credit facility suggest continued investor optimism. RBC Capital maintains an Outperform rating with a $13.00 price target. This article was generated with AI support and editor review.
New Credit Facility and Rating Upgrades Might Change The Case For Investing In AdaptHealth (AHCO)
AdaptHealth Corp. recently secured a US$1.10 billion senior secured credit facility, extending debt maturities and potentially reducing interest expenses. This new facility, alongside rating upgrades, may influence AdaptHealth's investment narrative by providing more financial flexibility to fund growth and manage existing debt. However, investors should remain aware of potential reimbursement pressures despite these positive financial developments.
AdaptHealth Credit Upgrade And New US$1.1b Facility Reshape Outlook
AdaptHealth (NasdaqCM:AHCO) has secured a new US$1.1 billion senior secured credit facility with improved terms, following recent credit rating upgrades. This refinancing adjusts the company's capital structure, affecting borrowing costs and debt maturities, and provides greater flexibility for future investments and growth initiatives. The move is significant for investors watching the healthcare services sector, as it impacts AdaptHealth's balance sheet strategies and its capacity to fund operations.
New Credit Facility and Rating Upgrades Might Change The Case For Investing In AdaptHealth (AHCO)
AdaptHealth Corp. recently secured a new US$1.10 billion senior secured credit facility following rating upgrades, which aims to extend debt maturities and potentially reduce its overall cost of debt. This move is expected to enhance the company's financial flexibility, support its growth initiatives, and fund its infrastructure for a multi-year national health system contract, though reimbursement and policy risks remain. The credit facility could positively influence AdaptHealth's investment outlook by improving its balance sheet and providing capital for M&A, aligning with its strategy for disciplined capital allocation.
Is AdaptHealth Corp (AHCO) Overvalued After 4.7% Rally? GF Value
AdaptHealth Corp (AHCO) shares rallied 4.7% to $12.71, but GuruFocus' GF Value indicates the stock is 25.0% overvalued with an intrinsic value of $10.17. Despite a GF Score of 74/100 suggesting above-average long-term returns and recent insider buying totalling $48.8 million, concerns remain regarding its financial strength and profitability. Investors are advised to be cautious due to the stock trading at a premium to its intrinsic value.
AdaptHealth (NasdaqCM:AHCO) Stock Forecast & Analyst Predictions
AdaptHealth (AHCO) is forecast to achieve significant earnings growth of 64.6% per annum, with EPS growing by 60.5% annually. Despite some analyst caution regarding recent operational challenges and legal costs, the company is expected to become profitable within the next three years. Analysts have provided mixed price target adjustments, reflecting a balance between growth prospects and near-term pressures.
A Look At AdaptHealth (AHCO) Valuation After Recent Share Price Momentum
AdaptHealth (AHCO) has seen significant share price momentum recently, with returns of 28% over the past month. Despite trading at US$12.66, analysts broadly agree the stock is undervalued with a fair value of $17.00, driven by expectations from a new five-year capitated contract and efficiency upside. However, potential challenges include CMS reimbursement cuts or execution risks on large contracts.
